Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 20

1390P - Real-world characteristics, treatment patterns and outcomes of patients with advanced HER2/ERBB2-mutant non-small cell lung cancer (NSCLC) in France and Germany

Date

21 Oct 2023

Session

Poster session 20

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Petros Christopoulos

Citation

Annals of Oncology (2023) 34 (suppl_2): S755-S851. 10.1016/S0923-7534(23)01943-9

Authors

P. Christopoulos1, N. Girard2, L. Zhang3, Z. Mbanya4, K. Dunton3, A. Ali5, M. Berktas6, L. Delmastro7, A. Struebing8, Y. Xiong9, S. Lay-Flurrie10, P. Hindocha10, T. Mehdikhanova11

Author affiliations

  • 1 Dept. Of Oncology Of Thoracic Tumors, Thoraxklinik Heidelberg gGmbH, 69126 - Heidelberg/DE
  • 2 Thorax Institute, Institut Curie, 75005 - Paris/FR
  • 3 Heor, Daiichi Sankyo Europe GmbH, 81379 - Munich/DE
  • 4 Global Health Economics & Payer Evidence, AstraZeneca UK, LU1 3LU - Luton/GB
  • 5 Global Oncology Medical Affairs, Daiichi Sankyo Europe GmbH, 81379 - Munich/DE
  • 6 Global Oncology Outcome Research, AstraZeneca - City House L1 and L3, CB2 1RE - Cambridge/GB
  • 7 Global Medical Affairs, AstraZeneca, CB4 0WG - Cambridge/GB
  • 8 Heor, Daiichi Sankyo Europe GmbH, 82152 - Martinsried (Planegg)/DE
  • 9 Real World Evidence, Daiichi Sankyo International, 07920 - Basking Ridge/US
  • 10 Real World Evidence, IQVIA, EH54 7EG - Livingston/GB
  • 11 Real World Evidence, IQVIA Ltd, W2 1AF - London/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1390P

Background

HER2 mutations (HER2m) are a potential therapeutic target in 2–3% of patients with non-squamous NSCLC; however, real-world evidence on demographics and outcomes is limited. We assessed patient characteristics and treatment patterns for advanced HER2m NSCLC at a French and a German academic centre.

Methods

Adults with advanced HER2m non-squamous NSCLC were identified at Institut Curie, France (study: 1 Jan 2011–22 Apr 2022) and Thoraxklinik Heidelberg, Germany (1 Jan 2014–5 May 2022). Lines of therapy (L) and treatment pathways were characterised. Demographic/clinical characteristics were analysed by descriptive statistics; survival was assessed by Kaplan–Meier analysis. Real-world progression-free survival (rwPFS) was time between L start and earliest progression event (Germany), discontinuation due to progression (France), next L start or death.

Results

Of 55 patients with advanced HER2m NSCLC (n=17, France; n=38, Germany), the median age at diagnosis was 66 years, 63.6% were female and 74.6% had ECOG scores of 0 or 1. 48 patients (87.3%) received at least 1L, 29 (52.7%) received at least 2L and 19 (34.5%) received at least 3L. The most common regimens were carboplatin + pemetrexed (13/48, 27.1%) and carboplatin + pemetrexed + pembrolizumab (9/48, 18.8%) in 1L and pembrolizumab (6/29, 21.0%), carboplatin + pembrolizumab + pemetrexed (3/29, 10.3%) and pemetrexed (3/29, 10.3%) in 2L. The most common treatment pathway began with non-platinum-based chemotherapy or platinum-based chemotherapy in 1L (26/48, 54.2%) and immunotherapy in 2L (7/26, 26.9%) (Table). Median real-world overall survival from the start of 1L was 16.5 months (95% CI: 12.3–29.8). Median rwPFS in the 1L was 5.1 months (95% CI: 3.5–8.5).

Conclusions

Chemotherapy was the mainstay in 1L; diverse regimens were used in 2L. Poor survival suggests a need for novel therapeutic options for advanced HER2m NSCLC. Table: 1390P

Regimen 1L (n=48) 2L (n=29) 3L (n=19)
n % n % n %
HER2 targeteda 1 2.1 1 3.4 4 21.1
HER2 targeteda + IMT 0 0 0 0 1 5.3
HER2 targeteda + non-plat 0 0 4 13.8 0 0
IMT 3 6.3 8 27.6 1 5.3
IMT + non-HER2 targetedb + non-plat + plat 1 2.1 0 0 0 0
IMT + non-plat + plat 11 22.9 3 10.3 1 5.3
Non-HER2 targetedb 1 2.1 1 3.4 0 0
Non-HER2 targetedb + non-plat 0 0 2 6.9 2 10.5
Non-HER2 targetedb + non-plat + plat 4 8.3 0 0 0 0
Non-plat 1 2.1 6 20.7 7 36.8
Non-plat + plat 26 54.2 4 13.8 3 15.8

aNeratinib, afatinib, poziotinib, trastuzumab, or trastuzumab emtansine. bAlectinib, bevacizumab, ceritinib, or ramucirumab. IMT, immunotherapy; non-plat, non-platinum-based chemotherapy; plat, platinum-based chemotherapy.

Clinical trial identification

Editorial acknowledgement

Medical writing and editorial assistance were provided by Julia C. Jones (PharmD, PhD), Erica Cave (PhD), and Daria Renshaw from IQVIA, funded by the study sponsors.

Legal entity responsible for the study

AstraZeneca, Daiichi Sankyo.

Funding

AstraZeneca, Daiichi Sankyo.

Disclosure

P. Christopoulos: Financial Interests, Personal, Advisory Board: AstraZeneca, Boehringer Ingelheim, Chugai, Pfizer, Novartis, MSD, Takeda, Roche, Daiichi Sankyo; Financial Interests, Personal, Writing Engagement: Gilead; Financial Interests, Personal, Invited Speaker: Thermo Fisher; Financial Interests, Institutional, Funding: AstraZeneca, Boehringer Ingelheim, Amgen, Novartis, Roche; Financial Interests, Personal, Funding: Takeda. N. Girard: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD, Roche, Pfizer, Mirati, Amgen, Novartis, Sanofi, Gilead; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Roche, Pfizer, Janssen, Boehringer, Novartis, Sanofi, AbbVie, Amgen, Lilly, Grunenthal, Takeda, Owkin, Leo Pharma, Daiichi Sankyo, Ipsen; Financial Interests, Institutional, Research Grant, Local: Roche, Sivan, Janssen; Financial Interests, Institutional, Funding: BMS, Leo Pharma; Financial Interests, Institutional, Research Grant: MSD; Non-Financial Interests, Officer, International Thymic malignancy interest group, president: ITMIG; Other, Family member is an employee: AstraZeneca. L. Zhang: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo; Financial Interests, Institutional, Funding, Funding for study and publication: Daiichi Sankyo, AstraZeneca. Z. Mbanya: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. K. Dunton: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo. A. Ali: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo; Financial Interests, Personal, Full or part-time Employment, Prior employer: AstraZeneca. M. Berktas: Financial Interests, Personal, Other, I receive regular consultancy fee for my scientific services, I am the project lead for the project from which 2 abstracts were created and submitted to ESMO 2023 congress: AstraZeneca. L. Delmastro: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Institutional, Funding, Funding for study & publication: AstraZeneca, Daiichi Sankyo. A. Struebing: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo. Y. Xiong: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo; Financial Interests, Personal, Full or part-time Employment, Prior employer: Becton Dickinson. S. Lay-Flurrie: Financial Interests, Personal, Full or part-time Employment: IQVIA; Financial Interests, Personal, Full or part-time Employment, Previous employer: University of Oxford; Financial Interests, Institutional, Funding, Funding for study & publication: AstraZeneca, Daiichi Sankyo. P. Hindocha: Financial Interests, Institutional, Funding, Funding for study & publication: AstraZeneca, Daiichi Sankyo; Financial Interests, Personal, Full or part-time Employment: IQVIA. T. Mehdikhanova: Financial Interests, Institutional, Funding, Funding for study and publication: AstraZeneca, Daiichi Sankyo; Financial Interests, Personal, Full or part-time Employment: IQVIA.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.